ABN 16 165 160 841

ASX RELEASE **12 May 2025**

AMPLIA APPOINTS DR JASON LICKLITER AS CHIEF MEDICAL OFFICER

- Amplia appoints Dr Jason Lickliter MBBS, FRACP as Chief Medical Officer
- Dr Lickliter brings a wealth of experience in oncology and clinical trials research

Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company") is pleased to announce the appointment of experienced oncologist and clinical trial specialist Dr Jason Lickliter MBBS, FRACP as Chief Medical Officer.

Dr Lickliter is a highly experienced and credentialed clinician with extensive experience in running and overseeing clinical trials. Dr Lickliter trained as a medical oncologist in Australia and at the University of Minnesota and has extensive experience in designing and implementing early-phase patient and healthy-volunteer clinical trials, including the integration of biomarker studies and advanced imaging into clinical research. Dr Lickliter has been acting in the role of clinical adviser to Amplia since 2021, chairing the Company's clinical trial safety committee and advising on the Phase 1 trial of narmafotinib in healthy volunteers and on the ongoing ACCENT trial.

Dr Lickliter will initially be employed in a part-time capacity, whilst also continuing in his existing role as Chief Medical Officer at Nucleus Network, a multi-centre phase 1 clinical trials organization.

Amplia CEO and MD Dr Chris Burns commented: "We are delighted that Dr Lickliter is joining the team at Amplia. It's an exciting time for the Company as we near important data readouts for the ongoing ACCENT Phase 2a trial and with the FOLFIRINOX combination Phase 1b/2a trial shortly to start. Jason's involvement and contributions as CMO will be critical to help guide our ongoing clinical activities."

Dr Lickliter commented: "I am thrilled to be joining Amplia at this exciting time. I have thoroughly enjoyed working with the team as an adviser up to this point, and I am looking forward to becoming more deeply embedded in the science and clinical activities. The data we have already seen with narmafotinib in the ACCENT trial is extremely encouraging."

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

About Narmafotinib

Narmafotinib (AMP945) is the company's best-in-class inhibitor of the protein FAK, a protein over-expressed in pancreatic cancer and a drug target gaining increasing attention for its role in solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. The drug successfully completed a healthy volunteer study in 2021 and is currently being investigated in advanced pancreatic cancer in the ACCENT trial. The drug

has Fast-Track and Orphan Drug Designation for pancreatic cancer from the US FDA. Plans for a US trial, under an open IND, in combination with FOLFIRINOX are well advanced.

About the ACCENT Trial

The ACCENT trial is entitled '*A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination with Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients*'.

The trial is a single-arm open label study conducted in two stages. The first stage (Phase 1b), completed in November 2023, determined an optimal dose of narmafotinib (AMP945) by assessing the safety, tolerability, pharmacokinetics and preliminary efficacy when dosed in combination with gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer.

The second stage (Phase 2a) of the trial is designed to assess efficacy in combination with gemcitabine and Abraxane. The primary endpoints are Objective Response Rate (ORR) and Duration on Trial (DOT) with secondary endpoints being Progression Free Survival (PFS) and Overall Survival (OS). Safety and tolerability will continue to be assessed. A total of 55 patients have been enrolled in the trial which is being conducted at seven sites in Australia and five sites in South Korea.

More information about the ACCENT trial can be found via the ACCENT trial site, the Amplia Therapeutics website and at ClinicalTrials.gov under the identifier NCT05355298.

About the FOLFIRINOX Trial

Narmafotinib, in combination with the modified FOLFIRINOX chemotherapy regimen, will explore the safety, tolerability, efficacy and pharmacokinetics of the combination in newly-diagnosed patients with advanced (metastatic) pancreatic cancer. The trial is entitled '*A Phase 1b/2a, Multicenter, Open Label Study of the Safety, Efficacy and Pharmacokinetics of narmafotinib in Combination with modified FOLFIRINOX in Pancreatic Cancer Patients*' and is being conducted under an open IND from the US FDA.

Designed as a single-arm, open-label study, the trial will proceed in two parts. Part A will explore a range of doses of narmafotinib (AMP945), taken once daily in combination with modified FOLFIRINOX administered every 14 days, for safety, tolerability, and pharmacokinetics. Part B of the trial is designed to identify the optimal daily dose of narmafotinib for future studies, by comparing two (2) doses identified from Part A, for safety, tolerability and efficacy.

The trial is being conducted initially at sites in the US and Australia.

Investor Contact:
Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

Media Contact:
H^CK Director, Haley Chartres
haley@hck.digital
+61 423 139 163

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on Twitter (@ampliatx) and LinkedIn.